Sector
PharmaceuticalsOpen
₹450Prev. Close
₹444.35Turnover(Lac.)
₹4,370.23Day's High
₹466.55Day's Low
₹445.152 Week's High
₹490.5552 Week's Low
₹112.35Book Value
₹49.74Face Value
₹1Mkt Cap (₹ Cr.)
2,848.77P/E
0EPS
0Divi. Yield
031 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
16 Sep 2024
12:00 AM
BookCloser
17 Sep 2024
12:00 AM
AGM
Announcement Date: 17 Sep, 2024
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 27.78 | 27.78 | 27.78 | 27.78 |
Preference Capital | 5.99 | 4.98 | 0 | 0 |
Reserves | 301.36 | 297.87 | 387.32 | 480.39 |
Net Worth | 335.13 | 330.63 | 415.1 | 508.17 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 343.55 | 158.08 | 576.56 | 530.08 |
yoy growth (%) | 117.32 | -72.58 | 8.76 | -18.05 |
Raw materials | -176.26 | -58.52 | -196.99 | -168.83 |
As % of sales | 51.3 | 37.02 | 34.16 | 31.84 |
Employee costs | -59.47 | -46.64 | -136.73 | -132.2 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -12.85 | -63.52 | -61.23 | -46.5 |
Depreciation | -26.57 | -26.9 | -57.04 | -66.14 |
Tax paid | -1.56 | -17.09 | -10.64 | 11.38 |
Working capital | -357.74 | 386.41 | -54.89 | 14.93 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 117.32 | -72.58 | 8.76 | -18.05 |
Op profit growth | -100.78 | -176.42 | 17.18 | -38.24 |
EBIT growth | -90.84 | -238.73 | -26.33 | -14.6 |
Net profit growth | -90.56 | 112.96 | -1.08 | -8,451.83 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 559.17 | 459.95 | 661.23 | 624.81 | 544.06 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 559.17 | 459.95 | 661.23 | 624.81 | 544.06 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 61.83 | 154.32 | 1,687.18 | 10.06 | 30.02 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,770 | 130.56 | 4,11,306 | 1,181.05 | 0.79 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,763 | 72.52 | 1,50,342.82 | 594 | 0.53 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,495.7 | 25.21 | 1,17,322.54 | 1,438.15 | 0.89 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,247.7 | 59.54 | 1,08,614.11 | 485 | 0.87 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,427.7 | 51.66 | 99,891.45 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Rajesh Jain
Joint Managing Director
Sandeep Jain
Group CFO & Company Secretary
Vinod Goel
Non-Exec. & Independent Dir.
Mukul Gupta
Whole-time Director
Ankesh Jain
Non-Exec. & Independent Dir.
BHUPINDER SINGH
Independent Director
Ambika Sharma
Non Executive Director
Krishan Kumar Jalan
Non Executive Director
Rajender Pal Singh
Whole Time Director
Harshet Jain
Whole Time Director
Sanjay Trehan
Independent Director
Venkatesh Sarvasiddhi
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Panacea Biotec Ltd
Summary
Indias leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on February 2, 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. PBL has ultra modern, state-of-art production facilities at Himachal Pradesh, Punjab & Delhi for manufacturing vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards and it has four research and development centers. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBLs Research & Dev
Read More
What is the Panacea Biotec Ltd share price today?
The Panacea Biotec Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹465.1 today.
What is the Market Cap of Panacea Biotec Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Panacea Biotec Ltd is ₹2848.77 Cr. as of 03 Apr ‘25
What is the PE and PB ratio of Panacea Biotec Ltd?
The PE and PB ratios of Panacea Biotec Ltd is 0 and 8.60 as of 03 Apr ‘25
What is the 52 Week High and Low of Panacea Biotec Ltd?
The 52-week high/low is the highest and lowest price at which a Panacea Biotec Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Panacea Biotec Ltd is ₹112.35 and ₹490.55 as of 03 Apr ‘25
What is the CAGR of Panacea Biotec Ltd?
Panacea Biotec Ltd's CAGR for 5 Years at 30.85%, 3 Years at 39.59%, 1 Year at 228.54%, 6 Month at 37.42%, 3 Month at 3.70% and 1 Month at 48.71%.
What is the shareholding pattern of Panacea Biotec Ltd?
The shareholding pattern of Panacea Biotec Ltd is as follows:
Promoters - 72.49 %
Institutions - 1.55 %
Public - 25.97 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
